azd5069

AZD5069 is an orally bioavailable, potent, selective and reversible small-molecule antagonist of the CXC chemokine receptor 2 (CXCR2), also known as the interleukin 8B receptor. Developed by AstraZeneca, it inhibits CXCR2-mediated signaling by directly binding to the receptor. This action reduces neutrophil recruitment and migration from systemic circulation into sites of inflammation such as lung mucosa and may prevent neutrophil migration from bone marrow. The resulting effects include reduced inflammation, mucus production, and tissue destruction in inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD). Additionally, CXCR2 is upregulated in various tumor types; thus AZD5069 has potential anti-inflammatory and antineoplastic activities[1][4][5].

Other names

CXC chemokine receptor 2 antagonist AZD5069N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamideUNII-4ADT8JXB9SUNII4ADT8JXB9SUNII 4ADT8JXB9S